Frank McCormick
RAS biologist who founded Onyx Pharmaceuticals and led the NCI's national effort to drug RAS.
Molecular biologist who worked on RAS signalling for four decades, founded Onyx (sorafenib, carfilzomib origins), and served as scientific lead of the NCI RAS Initiative at Frederick National Laboratory.
| Title | Journal | Year |
|---|---|---|
| KRAS as a Therapeutic Target | Clinical Cancer Research | 2015 |
| Sticking it to KRAS: Covalent Inhibitors Enter the Clinic | Cancer Cell | 2020 |
Pages like this
not linked directly; found by shared links- PersonKevan M. Shokat
Shares UCSF Helen Diller Family Comprehensive Cancer Center, KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
- ProductOlomorasib
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- ProductElironrasib
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- ProductMRTX1133
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- CompanyFrontier Medicines
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- ProductDivarasib
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer, Non-small-cell lung cancer.
- Key paperOstrem and Shokat: the hidden pocket that made KRAS G12C druggable
Shares UCSF Helen Diller Family Comprehensive Cancer Center, KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma.
- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares KRAS & RAS inhibitors, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.